Skip to content
HowShorted

Fate Therapeutics, Inc. short interest in 2021

In 2021, Fate Therapeutics, Inc.'s disclosed short interest ran from 11.64% of shares outstanding on 15 Jan 2021 to 12.04% on 31 Dec 2021, a change of +0.40 percentage points. The year's high was 14.02% on 30 Apr 2021 and its low 10.62% on 15 Nov 2021, averaging 12.32% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.34 days on 28 May 2021. Full history: Fate Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Fate Therapeutics, Inc. in 2021

2021 in figures

Start of year
11.64% (15 Jan 2021)
End of year
12.04% (31 Dec 2021)
Change
+0.40 pp
High
14.02% (30 Apr 2021)
Low
10.62% (15 Nov 2021)
Average
12.32%
Highest days to cover
19.34 (28 May 2021)
SEC filings marked
8

Every report in 2021

Fate Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202111.64%7.58
29 Jan 202111.55%10.29
12 Feb 202111.04%14.89
26 Feb 202111.81%10.5510-K filed, results (8-K)
15 Mar 202113.26%12.39
31 Mar 202113.82%11.21
15 Apr 202113.83%14.41
30 Apr 202114.02%17.90
14 May 202113.85%12.3210-Q filed, results (8-K)
28 May 202112.94%19.34
15 Jun 202112.53%9.59
30 Jun 202112.59%12.22
15 Jul 202112.38%12.61
30 Jul 202113.00%16.43
13 Aug 202112.95%18.1310-Q filed, results (8-K)
31 Aug 202112.54%7.24
15 Sep 202112.39%12.17
30 Sep 202111.97%11.70
15 Oct 202111.30%12.16
29 Oct 202110.82%9.79
15 Nov 202110.62%13.6210-Q filed, results (8-K)
30 Nov 202111.37%11.65
15 Dec 202111.33%7.48
31 Dec 202112.04%8.20

See also: Fate Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.